"Neprilysin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Enzyme that is a major constituent of kidney brush-border membranes and is also present to a lesser degree in the brain and other tissues. It preferentially catalyzes cleavage at the amino group of hydrophobic residues of the B-chain of insulin as well as opioid peptides and other biologically active peptides. The enzyme is inhibited primarily by EDTA, phosphoramidon, and thiorphan and is reactivated by zinc. Neprilysin is identical to common acute lymphoblastic leukemia antigen (CALLA Antigen), an important marker in the diagnosis of human acute lymphocytic leukemia. There is no relationship with CALLA PLANT.
Descriptor ID |
D015260
|
MeSH Number(s) |
D08.811.277.656.300.480.600 D08.811.277.656.675.374.600 D23.050.285.550 D23.101.140.500
|
Concept/Terms |
Neprilysin- Neprilysin
- CALLA Antigen
- Enkephalinase
- Enkephalinase-24.11
- Enkephalinase 24.11
- Kidney-Brush-Border Neutral Proteinase
- Kidney Brush Border Neutral Proteinase
- Neutral Proteinase, Kidney-Brush-Border
- Membrane Metallo-Endopeptidase
- Membrane Metallo Endopeptidase
- Metallo-Endopeptidase, Membrane
- Neutral Endopeptidase
- Endopeptidase, Neutral
- Neutral Endopeptidase 24.11
- Endopeptidase 24.11, Neutral
- Thermolysin-Like Metalloendopeptidase
- Metalloendopeptidase, Thermolysin-Like
- Thermolysin Like Metalloendopeptidase
- YGG-Forming Enzyme
- Enzyme, YGG-Forming
- YGG Forming Enzyme
- Common Acute Lymphoblastic Leukemia Antigens
- Antigens, Leukemia, Common Acute Lymphoblastic
- Atriopeptidase
- CD10 Antigen
- Antigen, CD10
- Antigens, CD10
- CD10 Antigens
- Endopeptidase-24.11
- Endopeptidase 24.11
- Enkephalin Dipeptidyl Carboxypeptidase
- Carboxypeptidase, Enkephalin Dipeptidyl
- Dipeptidyl Carboxypeptidase, Enkephalin
|
Below are MeSH descriptors whose meaning is more general than "Neprilysin".
Below are MeSH descriptors whose meaning is more specific than "Neprilysin".
This graph shows the total number of publications written about "Neprilysin" by people in this website by year, and whether "Neprilysin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2004 | 1 | 0 | 1 |
2009 | 0 | 1 | 1 |
2012 | 0 | 1 | 1 |
2015 | 1 | 1 | 2 |
2017 | 8 | 7 | 15 |
2018 | 8 | 10 | 18 |
2019 | 3 | 8 | 11 |
2020 | 0 | 1 | 1 |
2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Neprilysin" by people in Profiles.
-
Broadening COVID-19 Interventions to Drug Innovation: Neprilysin Pathway as a Friend, Foe, or Promising Molecular Target? OMICS. 2021 07; 25(7):408-416.
-
Between two storms, vasoactive peptides or bradykinin underlie severity of COVID-19? Physiol Rep. 2021 03; 9(5):e14796.
-
Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19. Med Hypotheses. 2021 Feb; 147:110486.
-
The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19. Int J Mol Sci. 2020 Nov 15; 21(22).
-
The Cross-Talk between Age, Hypertension and Inflammation in COVID-19 Patients: Therapeutic Targets. Drugs Aging. 2020 11; 37(11):779-785.
-
New putative insights into neprilysin (NEP)-dependent pharmacotherapeutic role of roflumilast in treating COVID-19. Eur J Pharmacol. 2020 Dec 15; 889:173615.
-
Neprilysin expression and functions in development, ageing and disease. Mech Ageing Dev. 2020 12; 192:111363.
-
Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients. Eur Heart J Cardiovasc Pharmacother. 2020 07 01; 6(3):135-136.
-
Sacubitril/valsartan in COVID-19 patients: the need for trials. Eur Heart J Cardiovasc Pharmacother. 2020 07 01; 6(4):253-254.
-
Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost. Biochem Pharmacol. 2020 08; 178:114057.